Sareum Holdings awarded grant for breast cancer chemical series

Cancer drug discovery business Sareum Holdings has been offered a grant from funding programme Biomedial Catalyst, which will provide financial support for the company's Fatty Acid Synthase (FASN) research programme.

Cancer drug discovery business Sareum Holdings has been offered a grant from funding programme Biomedial Catalyst, which will provide financial support for the company's Fatty Acid Synthase (FASN) research programme.

The £150,000 grant funding will enable Sareum to explore further the potential of its novel chemical series, which shows promising efficacy in breast cancel cell models, over the next nine months.

Sareum will receive the grant on the condition it contributes up to £50,000 from its working capital during the funding period, as well as a compliance review by the Technology Strategy Board and an agreement between both parties.

Sareum's Chief Executive, Dr. Tim Mitchell, said: "We are delighted to have been offered this financial support from the Biomedical Catalyst, which gives us the opportunity to demonstrate the potential of our novel FASN inhibitors.

"Success from this funding period may open up the opportunity of additional awards to advance further the programme. We believe this award is a positive validation of Sareum's science as competition for these grants is very strong."

The share price climbed 2.% to 1.02p by 09:37.

NR

Recommended

Three sustainable stocks that are doing well by doing good
Share tips

Three sustainable stocks that are doing well by doing good

Professional investor Peter Michaelis of the Liontrust Sustainable Investment Team picks three stocks to buy that are helping to create a cleaner, saf…
26 Jul 2021
Share tips of the week – 23 July
Share tips

Share tips of the week – 23 July

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
23 Jul 2021
Will Zoom’s $15bn purchase help it expand?
Tech stocks

Will Zoom’s $15bn purchase help it expand?

The videoconferencing platform became a household name during the pandemic, but it now needs new sources of growth. Alex Rankine reports
23 Jul 2021
Philip Morris goes “beyond nicotine”
Stocks and shares

Philip Morris goes “beyond nicotine”

US tobacco giant Philip Morris International has agreed to pay £1bn for British inhaler specialist Vectura.
23 Jul 2021

Most Popular

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism
Economy

The MoneyWeek Podcast: Asia, financial repression and the nature of capitalism

Russell Napier talks to Merryn about financial repression – or "stealing money from old people slowly" – plus how Asian capitalism is taking over in t…
16 Jul 2021
Why the UK's 2.5% inflation is a big deal
Inflation

Why the UK's 2.5% inflation is a big deal

After years of inflation being a financial-assets problem, it is now an “ordinary things” problem too, says Merryn Somerset Webb. But central banks st…
16 Jul 2021
Three companies that are reaping the rewards of investment
Share tips

Three companies that are reaping the rewards of investment

Professional investor Edward Wielechowski of the Odyssean Investment Trust highlights three stocks that have have invested well – and are able to deal…
19 Jul 2021